Observational Cohort of COVID-19 Patients in Hubei Province

Completed

• Conditions: 2019 Novel Coronavirus Disease
• Interventions: Other: No intervention

• Registration Number: NCT05615792
• Lead Sponsor: Dao Wen Wang

Brief Summary

This study intends to use the relevant case data of COVID-19 in Hubei Province, using big data processing and mining methods to evaluate the effects of clinical indicators, drug use and genes on the clinical prognosis of COVID-19 patients, so as to provide a theoretical basis for the treatment of these diseases and reduce the mortality.

Detailed Description

Hubei Province, as the forefront of the fight against epidemic, has the largest number of patients infected with SARS-CoV-2 and the highest quality medical data. However, so far, these data have not been fully analyzed, if these data can not be mined and used, it will be a great loss to the whole human race. By fully mining and analyzing these data, we can sum up a large number of experiences related to COVID-19, summarize various laws of this kind of disease, and provide clinical evidence based on large samples for the research of this disease, eventually contribute China's experience to the global fight against the epidemic.

Based on the above background, this study intends to use the relevant case data of COVID-19 in Hubei Province, using big data processing and mining methods to evaluate the effects of clinical indicators, drug use and genes on the clinical prognosis of COVID-19 patients, so as to provide a theoretical basis for the treatment of these diseases and reduce the mortality.

Study Timeline

• Study Start: 2020-02-01
• Study First Submitted: 2022-11-10
• Study First Submitted QC: 2022-11-10
• Study First Posted: 2022-11-14
• Status Verified: 2024-03
• Primary Completion: 2024-03-01
• Study Completion: 2024-03-01
• Last Update Submitted: 2024-03-06
• Last Update Posted: 2024-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 68000

Inclusion Criteria

1. Age ≥ 18, regardless of gender;
2. A history of epidemiology, including travel or residence in high-risk areas or other communities with case reports within 14 days before the onset of the disease, or have a history of contact with novel coronavirus infection (those who are positive for nucleic acid tests); or patients with fever or respiratory symptoms from the community with case reports; or aggregative onset;
3. Corresponding clinical manifestations, including respiratory symptoms such as fever, with typical imaging features of COVID-19, normal or decreased white blood cell count and decreased lymphocyte count in the early stage of the disease;
4. Clear etiological evidence, including real-time fluorescent RT-PCR detection of novel coronavirus nucleic acid positive, or viral gene sequencing, is highly homologous to novel coronavirus.

Exclusion Criteria

Patients who meet any of the following criteria cannot be enrolled in this study:

1. Patients refused to participate in this study;
2. According to the researchers, patients are unable to complete this study or comply with the requirements of this study (due to management or other reasons).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with coronavirus disease 2019 (COVID-19)	No intervention	Patients diagnosed with COVID-19 in Hubei Province

Primary Outcome Measures

Name	Time	Method
All-cause mortality	2 years	Numbers and dates of death in each group

Trial Locations

Locations (1)

Tongji Hospital; 🇨🇳 Wuhan, Hubei, China